Going Concern (new) — Auditor's report now includes going-concern paragraph citing recurring losses and substantial doubt about ability to continue operations.
Material Weakness (removed) — Previously disclosed material weakness in internal controls has been remediated and is no longer reported in current filing.

NASDAQ: VVOS Vivos Therapeutics, Inc. 10-K

VVOS acquires sleep center, shifts to medical model; net loss doubles, cash falls 68%

Filed April 15, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade VVOS commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 3, 2026 4:17 AM